NCT00177138View on ClinicalTrials.gov

Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

PHASE4TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

November 30, 2006

Conditions
Diabetes Mellitus
Interventions
DRUG

Tacrolimus

Starting POD #1 0.06 mg/kg/day in 2 divided doses;

DRUG

Alemtuzumab

30 mg IV intra-op and POD #12; then 30 mg IV \>monthly for 1 year (only if ALC\>200 mm, up to a total of 10 doses in year)

Trial Locations (1)

55414

University of Minnesota-Fairview, Minneapolis

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Gruessner, Rainer, MD

UNKNOWN

lead

University of Minnesota

OTHER